Your browser doesn't support javascript.
loading
Understanding the relationship between HCV infection and progression of kidney disease.
Zhang, Meiqi; Han, Zhongyu; Lin, Yumeng; Jin, Zi; Zhou, Shuwei; Wang, Siyu; Tang, Yuping; Li, Jiaxuan; Li, Xueping; Chen, Haoran.
Affiliation
  • Zhang M; School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
  • Han Z; School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
  • Lin Y; Naniing Tongren Hospital, School of Medicine, Southeast University, Nanjing, China.
  • Jin Z; Naniing Tongren Hospital, School of Medicine, Southeast University, Nanjing, China.
  • Zhou S; Department of Anesthesiology and Pain Rehabilitation, Shanghai YangZhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), School of Medicine, Tongji University, Shanghai, China.
  • Wang S; Jiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
  • Tang Y; Department of Gastroenterology, The First Hospital of Hunan University of Chinese Medicine, Changsha, China.
  • Li J; Hepatobiliary Department of the Third Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, Nanning, Guangxi, China.
  • Li X; School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
  • Chen H; School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Front Microbiol ; 15: 1418301, 2024.
Article de En | MEDLINE | ID: mdl-39006752
ABSTRACT
Hepatitis C virus (HCV) can cause a range of kidney diseases. HCV is the primary cause of mixed cryoglobulinaemia, which leads to cryoglobulinaemic vasculitis and cryoglobulinaemic glomerulonephritis (GN). Patients with acute cryoglobulinaemic vasculitis often exhibit acute kidney disease due to HCV infection, which typically progresses to acute kidney injury (AKI). HCV also increases the risk of chronic kidney disease (CKD) and the likelihood of developing end-stage renal disease (ESRD). Currently, direct-acting antiviral agents (DAAs) can be used to treat kidney disease at different stages. This review focuses on key findings regarding HCV and kidney disease, discusses the impact of DAAs, and highlights the need for further research and treatment.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Front Microbiol Année: 2024 Type de document: Article Pays d'affiliation: Chine

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Front Microbiol Année: 2024 Type de document: Article Pays d'affiliation: Chine